Axogen Inc. Common Stock
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
AXGN Overview
Sector |
Health Care |
Industry |
Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Previous Close |
$8.7600 |
Previous Close Volume |
121060 |
Latest News
- Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update 07 Nov 2024 07:01:02
- Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024 24 Oct 2024 07:03:43
-
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
06 Sep 2024 07:01:04
https://ir.axogeninc.com/press-releases/detail/990/axogen-completes-submission-of-biologics-license
- Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) 03 Sep 2024 07:01:05
-
Axogen, Inc. Announces New Leadership Appointments
08 Aug 2024 07:18:46
https://ir.axogeninc.com/press-releases/detail/988/axogen-inc-announces-new-leadership-appointments
- Axogen, Inc. Reports Second Quarter 2024 Financial Results 08 Aug 2024 07:03:44
- Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 23 Jul 2024 07:03:46
- Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) 01 Jul 2024 07:03:49
- Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™ 24 Jun 2024 07:03:46
- Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia 28 May 2024 16:31:24
- Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft® 16 May 2024 07:03:46
- Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference 14 May 2024 07:03:51
- Axogen, Inc Reports First Quarter 2024 Financial Results 02 May 2024 07:03:50
- Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™ 29 Apr 2024 17:03:47
- Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 16 Apr 2024 07:03:50
- Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results 05 Mar 2024 07:03:48
- Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024 13 Feb 2024 16:33:48
- Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) 02 Feb 2024 16:18:51
- Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap 18 Jan 2024 17:03:51